Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Lifestyle interventions reduce need for antihypertensive medication in overweight people

Researchers found that assigning overweight patients to the DASH diet and a behavioural weight management programme cut the number of patients eligible for antihypertensive medication

Lifestyle interventions to improve nutrition and exercise can cut the number of overweight and obese people who are eligible for antihypertensive medicines, according to an analysis presented at the American Heart Association Joint Hypertension 2018 Scientific Sessions in Chigago, Illinois[1].

Researchers studied data on 129 overweight or obese individuals aged 40–80 years old with a blood pressure reading of 130­–160mmHg/80–99mmHg who were randomly assigned to follow either the DASH (Dietary Approaches to Stop Hypertension) diet; the DASH diet plus a behavioural weight management programme; or to continue with their normal habits.

The DASH diet places an emphasis on fruit, vegetables and wholegrains, and limits sugar and saturated fat consumption.

Before the trial, 53% of individuals across the three groups were eligible for antihypertensive treatment, according to US guidelines.

At the end of the intervention, individuals eligible for treatment fell from 51% to 23% in the DASH alone group and from 54% to 15% in the DASH plus weight management group. It did not change significantly in the control group (55% to 48%).

“In overweight or obese men and women with hypertension, lifestyle interventions dramatically decrease the number of individuals for whom guideline-directed antihypertensive medication is indicated,” the researchers concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205529

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.